Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. Issue 10 (2nd October 2016)

• Record Type: Journal Article
• Authors: Zheng, Ji-Na; Zou, Tian-Tian; Zou, Hai; Zhu, Gui-Qi; Ruan, Lu-Yi; Cheng, Zhang; Van Poucke, Sven; Zheng, Ming-Hua
• Is Part Of: Expert review of anti-infective therapy. Volume 14:Issue 10(2016)
• Page Start: 979
• Page End: 987
• Publication Date: 2016-10-02
• Subjects: Hepatitis B virus recurrence -- nucleos(t)ide analogues prophylaxis -- liver transplantation -- network meta-analysis -- indirect comparison; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2016.1220831
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Background: Prophylactic nucleos(t)ide anologues against hepatitis B virus (HBV) recurrence after liver transplantation (LT) include lamivudine, entecavir, tenofovir, adefovir. Since the most effective strategies for post-LT remain inconclusive, we aimed to compare 6 different treatment options (lamivudine, entecavir, tenofovir, adefovir, lamivudine plus adefovir, lamivudine plus tenofovir) in terms of HBV recurrence after LT using network meta-analysis. Methods: The search identified seventeen studies involving 6 different prophylactic regimens covering 7274 patients. Results: Compared with entecavir, lamivudine plus tenofovir (OR 2.00, 95%CI 0.02-183.29), lamivudine plus adefovir, (OR 2.83, 95%CI 0.18-33.57), tenofovir (OR 1.11, 95%CI 0.22-5.80), adefovir (OR 3.78, 95%CI 0.59-22.16), lamivudine (OR 4.62, 95%CI 1.75-11.39) were associated with an increased risk of HBV recurrence. Conclusion: Entecavir resulted with the highest probability (31%) as the best prophylactic option on reducing the risk of HBV recurrence. Entecavir is the preferred oral NAs treatment compared to other five different prophylactic regimens in the prevention of HBV recurrence after LT.